COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment

Condition: Non-Small Cell Lung Cancer

Sponsor: Janssen Research & Development, LLC

Full Title
Protocol 61186372NSC2012: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study Treatment
Amivantamab, a bispecific antibody targeting EGFR and MET in combination with lazertinib, an EGFR tyrosine kinase inhibitor.

Eligibility/Info
Eligible patients will have an advanced/metastatic non-small cell lung cancer with an EGFR exon 19 deletion or EGFR L858R mutation and will not have received systemic anticancer therapy in the advanced/metastatic setting.

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage